PA007643.m1: In Vivo Grade Recombinant Anti-human CD105 Monoclonal Antibody (Clone: ahCD105), Mouse IgG1 Kappa
Recombinant mouse IgG1 Monoclonal Antibody.
Clone: ahCD105.
Isotype: Mouse IgG1 kappa.
Source: The anti-human CD105 monoclonal antibody (clone: ahCD105) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: ahCD105) specifically binds to human CD105.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD105 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human CD105 monoclonal antibody of clone ahCD105 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-human CD105 antibody (Clone: ahCD105):
Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Nair-Gill, E., et al. Clin Cancer Res. 2019 Aug 1;25(15):4656-4668. doi: 10.1158/1078-0432.CCR-19-0172. PMID: 31068371
The anti-CD105 antibody TRC105, combined with activated NK cells, mediated ADCC against MSCs, monocytes, and endothelial cells, overcoming the immunosuppressive effects of MSCs and monocytes in vitro. In NSG mice with neuroblastoma xenografts, TRC105 enhanced dinutuximab and aNK cell therapy, leading to improved tumor regression and depletion of CD105+ cells in the tumor microenvironment, as confirmed by histological analysis.
Tags: anti-human CD105 ahCD105 in vivo; anti-human CD105 ahCD105 antibody in vivo
PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment
Yang, X., et al. J Nucl Med. 2015 Jun;56(6):924-9. doi: 10.2967/jnumed.114.149815. PMID: 25883125
The Fab fragment of TRC105, a CD105-specific monoclonal antibody, was conjugated to NOTA for 64Cu labeling, enabling noninvasive PET imaging of abdominal aortic aneurysms in rats with enhanced contrast due to rapid kidney clearance. Ex vivo studies confirmed high CD105 expression and elastic fiber degradation, with immunofluorescence showing CD105 (green) and CD31 (red) expression in AAA samples.
Tags: anti-human CD105 ahCD105 antibody in animal model; anti-human CD105 ahCD105 mAb in animal model
Targeted antiangiogenesis gene therapy using targeted cationic microbubbles conjugated with CD105 antibody compared with untargeted cationic and neutral microbubbles
Wu, S., et al. Gene Ther. 2015 May;22(5):394-404. doi: 10.1038/gt.2015.8. PMID: 25699099
Cationic microbubbles (CMB105) conjugated with anti-CD105 antibody retained plasmid DNA binding ability and targeted HUVECs in vitro and tumor neovascularization in vivo, unlike untargeted CMB and neutral microbubbles. Binding specificity was confirmed by preincubation with anti-CD105 or isotype control antibodies, demonstrating CMB105's superior targeting efficiency in vivo.
Tags: anti-human CD105 ahCD105 antibody in vivo; anti-human CD105 ahCD105 in human tumor model
Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105
Zhang, X., et al. Eur J Nucl Med Mol Imaging. 2014 May;41(5):936-45. doi: 10.1007/s00259-013-2669-7. PMID: 24380040
PET imaging with 64Cu-NOTA-TRC105 revealed peak CD105 expression in the infarcted heart of female rats 7 days post-myocardial infarction (MI) induced by left anterior descending artery ligation. Tracer uptake decreased to background levels by day 17, with low uptake in sham rats. Histopathology corroborated increased CD105 expression post-MI.
Tags: function of anti-human CD105 ahCD105 mAb; bioactivity of anti-human CD105 ahCD105 mAb
Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies
Breton, S., et al. Int J Cancer. 1999 Sep 9;82(6):861-9. doi: 10.1002/(SICI)1097-0215(19990909)82:6<861::AID-IJC16>3.0.CO;2-#. PMID: 10417773
The 125I-labeled anti-endoglin antibodies SN6f and SN6j, targeting CD105 on proliferating endothelial cells, significantly inhibited growth of MDA-MB-231 and HT-29 tumors in SCID mice by reducing tumor vascularization. No significant toxicity was observed, highlighting the antibodies' antiangiogenic efficacy.
Tags: anti-human CD105 ahCD105 antibody of low endotoxin; anti-CD105 clone ahCD105
For more references about anti-human CD105 antibody (ahCD105), please contact our scientific support team with message@sydlabs.com.